Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma

Veselaj, Fahredin; Manxhuka-Kërliu, Suzana; Neziri, A.; Shahini, Labinot; Xharra, Shefki; Selmani, L.; Kerliu, Lloreta; Kavaja, Floren

doi:10.3889/oamjms.2017.035

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the research by Veselaj et al. demonstrated a higher expression of VEGF in tumor tissue in RCC patients than in normal kidney tissue, supported by our findings [ 31 ]. In research conducted by Nicol et al., results revealed VEGF overexpression in RCC but not in normal renal tissue [ 32 ].…”

Section: Discussionsupporting

confidence: 91%

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib

Kraljević

Marijanović

Barbarić

et al. 2022

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

The most common type of renal cell carcinoma (RCC) is clear cell renal cell carcinoma (ccRCC), which has a high metastatic potential. Even though the International Metastatic RCC Database Consortium (IMDC) risk model is conventionally utilized for selection and stratification of patients with metastatic RCC (mRCC), there remains an unmet demand for novel prognostic and predictive markers. The goal of this study was to analyze the expression of Vascular endothelial growth factor (VEGF), Cluster of Differentiation 31 (CD31) to determine microvessel density, and Angiopoietin-1 (Ang-1) in primary kidney tumors, as well as their predictive and prognostic value in patients with metastatic ccRCC (mccRCC) who were treated with first-line sunitinib. The study included 35 mccRCC patients who were treated with first-line sunitinib in period between 2009 and 2019. Immunofluorescence was used to examine biomarker expression in tissue specimens of the primary tumor and surrounding normal kidney tissue. Median disease-free survival (DFS) was longer in patients with negative and low tumor VEGF score than in patients with medium tumor VEGF score (p=0.02). Those with low tumor CD31 expression had a longer median DFS than patients with high tumor CD31 expression (p=0.019). There was no correlation between Ang-1 expression and DFS. The expression of biomarkers in normal kidney tissue was significantly lower than in tumor tissue (p<0.001). In conclusion, higher VEGF scores and greater CD31 expression were associated with longer DFS, but neither of these biomarkers correlated with progression-free survival or overall survival.

show abstract

Section: Discussionsupporting

confidence: 91%

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib

Kraljević

Marijanović

Barbarić

et al. 2022

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…This was similar to the studies done by Yildiz E et al, 16 Bürgesser M et al 18 and Osman WM et al 21 Expression of VEGF grades was seen to increase with the increase in stage of the tumours. This observation was found to be concordant with Ebru T et al, 19 Bürgesser M et al 18 and Osman WM et al 21 No significant difference was found in our study between different RCC types concerning cytoplasmic VEGF expression which is concordant with findings of Yildiz E et al 16 and Matušan-Ilijaš K et al 22 Furthermore, we noted that VEGF grade showed significant association with presence of necrosis and lymphovascular invasion which is similar to studies by Fujita N et al 23 and Veselaj F et al 24 In our study, we found the mean Ki-67 labelling index (mean ± s.d.) of the patients was 14.32 ± 3.88 with a range 5 -22 and the median was 15.0.…”

Section: Figure 1 Hande Photomicrographs Of Different Subtypes Of Rccssupporting

confidence: 91%

CORRELATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND Ki-67 EXPRESSION WITH HISTOLOGICAL GRADE AND STAGE OF RENAL CELL CARCINOMA

Chakraborty¹,

Sarkar²,

Bhattacharya³

et al. 2019

jemds

View full text Add to dashboard Cite

BACKGROUND Renal cell carcinoma (RCC) is the most common malignant kidney tumour in adults. The vascular endothelial growth factor (VEGF) is thought to play a major role in tumour angiogenesis. Ki-67 has been shown to be of prognostic significance in RCCs. With the availability of more effective molecular targeted therapy for specific renal neoplasms, immunohistochemical (IHC) techniques play an important role in diagnosis and prognostication of RCCs. This study aims to evaluate the expression pattern of VEGF and Ki-67 in histologically diagnosed cases of RCC and correlate and compare VEGF and Ki-67 expression with grade and stage of RCC and also compare VEGF expression and Ki-67 index if any. MATERIALS AND METHODS This was a cross-sectional observational study. A total of 50 patients of RCC undergoing total and partial nephrectomy were included in this study. The expressions of Ki-67 and VEGF were studied by IHC. Statistical Analysis was performed with the help of Epi Info (TM) 7.2.2.2. p value of ≤0.05 was considered statistically significant. RESULTS Out of 50 tumours, 21 tumours were VEGF Grade 1, 19 tumours were VEGF Grade 2. 27 tumours had Ki67 labelling index≥15%. There was significant association of VEGF grades and Ki-67 labelling index with stage and histological grade. Ki-67 labelling index showed significantly increasing trend with the increase in VEGF grades of the tumours. CONCLUSION This study suggests that there are significant differences in VEGF expression and Ki-67 labelling index with tumour stage and grade and other prognostic parameters of RCC. These biomarkers can be considered as a prognostic parameters and critical evaluator of targeted chemotherapy in RCC. A wider evaluation involving large number of cases with proper follow up facility is needed to validate these findings.

show abstract

“…Our findings demonstrated an increased cytoplasmic presence of VEGFA in cancer cells, consistent with previous reports (5,27,83-85). For example, Veselaj et al (84) and Dagher et al (5) observed that increased VEGFA immunoreactivity in tumor samples from ccRCC patients was associated with cancer progression and disease-free survival (5,84), as well as with an increased risk of death (84).…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment

et al. 2019

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell cancer, characterized by the highest mortality rate among other RCC subtypes due to the occurrence of metastasis and drug resistance following surgery. The Von Hippel-Lindau tumor suppressor (VHL)-hypoxia-inducible factor 1 subunit α (HIF1A)/hypoxia-inducible factor 2α (HIF2A)-vascular endothelial growth factor A (VEGFA) protein axis is involved in the development and progression of ccRCC, whereas sunitinib, a tyrosine kinase inhibitor, blocks the binding of VEGFA to its receptor. The aim of the present study was to examine the possible association of the gene expression of VHL, HIF1A, HIF2A, VEGFA and tumor protein P53 ( P53 ) in cancer tissue with the outcome of ccRCC patients who were treated with sunitinib as first-line therapy following nephrec-tomy. A total of 36 ccRCC patients were enrolled, 11 of whom were administered sunitinib post-operatively. Tumor and control samples were collected, and mRNA and protein levels were assessed by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. High mRNA and protein expression levels of HIF2A and VEGFA were found to be associated with shorter overall survival (OS) and progression-free survival (PFS) rates, as well as with unfavorable risk factors of cancer recurrence and mortality. Resistance to sunitinib was also observed; the OS and PFS rates were shorter (median OS and PFS: 12 and 6 months, respectively, vs. undetermined). Sunitinib resistance was associated with high HIF2A and VEGFA protein levels (b=0.57 and b=0.69 for OS and PFS, respectively; P<0.001). Taken together, the findings of this study suggest that the protein levels of HIF2A and VEGFA in tumor tissue may serve as independent prognostic factors in ccRCC. ccRCC patients with increased intratumoral HIF2A and VEGFA protein levels, and unaltered VHL protein levels, are not likely to benefit from sunitinib treatment following nephrectomy; however, this hypothesis requires verification by large-scale replication studies.

show abstract

Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma

Cited by 6 publications

References 22 publications

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib

CORRELATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND Ki-67 EXPRESSION WITH HISTOLOGICAL GRADE AND STAGE OF RENAL CELL CARCINOMA

Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment

Contact Info

Product

Resources

About